Phototherapeutic Keratectomy (PTK): Procedure, Indications, and Recovery — Overview, Diagnosis & Treatment Options | MyMedicPlus

Phototherapeutic keratectomy (PTK) is an excimer laser procedure that uses a 193-nanometer argon fluoride laser to ablate diseased or abnormal tissue from the anterior cornea. Unlike photorefractive keratectomy (PRK), which primarily corrects refractive errors, PTK targets pathological corneal tissue to improve corneal clarity, surface regularity, and comfort. The procedure is FDA-approved for the treatment of anterior corneal dystrophies, recurrent corneal erosion syndrome, corneal scars and opacities from infection or trauma, band keratopathy, and other superficial corneal disorders. PTK removes corneal tissue with sub-micron precision, ablating depths of 50–150 microns or more depending on the pathology. It can improve best-corrected visual acuity, reduce glare and photophobia, and relieve chronic ocular pain from erosions. PTK may be combined with concurrent refractive correction (PTK/PRK) to address induced hyperopic shift from ablation.

PTK addresses a range of anterior corneal pathologies. Corneal dystrophies treated include map-dot-fingerprint (epithelial basement membrane dystrophy), Reis-Bücklers dystrophy, Thiel-Behnke dystrophy, granular corneal dystrophy (GCD types 1 and 2), lattice corneal dystrophy, and Meesmann dystrophy. Recurrent corneal erosion syndrome — characterized by repeated painful spontaneous epithelial breakdown, often after minor injury — is one of the most common indications and responds well to PTK with low recurrence rates. Anterior corneal scars from bacterial keratitis, viral keratitis (herpes simplex, herpes zoster), corneal ulcers, or blunt trauma are treated when the opacity is anterior enough to be addressed without ablating through the visual axis stroma. Band keratopathy (calcium deposition in Bowman's layer) and Salzmann nodular degeneration are additional common indications. PTK is also used after failed penetrating keratoplasty to address surface irregularity.

The symptoms that prompt consideration of PTK depend on the underlying corneal condition. Recurrent corneal erosion presents with sudden-onset severe eye pain, tearing, photophobia, and blurred vision — typically upon awakening, when adhesion between the eyelid and poorly adherent epithelium causes tearing. Corneal opacities and dystrophies cause progressive glare, halos around lights, photophobia, and deteriorating vision — particularly in bright conditions. Granular dystrophy deposits cause progressively worsening contrast sensitivity even when Snellen acuity appears preserved. Band keratopathy creates chalky white corneal haze causing glare and reduced vision. Salzmann nodular degeneration causes irregular astigmatism and surface discomfort. Symptomatic impact on quality of life and failure to respond to conservative measures (lubricating drops, hypertonic saline ointments, bandage contact lenses) are the main indicators that PTK may offer benefit.

Careful pre-procedure evaluation ensures appropriate patient selection and optimizes outcomes. Slit-lamp biomicroscopy characterizes the nature, depth, and extent of corneal pathology. Confocal microscopy may identify the depth and layer of corneal dystrophy deposits. Corneal topography (Scheimpflug-based, e.g., Pentacam) maps the corneal curvature and identifies irregular astigmatism that may be addressable with concurrent PTK/PRK. Optical coherence tomography (OCT) of the anterior segment allows precise measurement of opacity depth and residual stromal thickness to ensure adequate stromal bed remains post-ablation. Endothelial cell count is assessed to confirm corneal health. Corneal genetic testing may identify specific dystrophies — particularly TGFBI mutation analysis for granular, Reis-Bücklers, and lattice dystrophies — which informs prognosis, recurrence risk, and family counseling. Best-corrected visual acuity, manifest refraction, and contrast sensitivity are measured to set realistic outcome expectations.

PTK is typically performed under topical anesthesia as an outpatient procedure. The epithelium is removed mechanically or by 'alcohol-assisted' debridement, or the laser may ablate through intact epithelium (transepithelial PTK). The excimer laser delivers 193-nm pulses in a large-area, 6.0–9.0 mm beam to ablate the targeted pathological stroma. Masking agents (methylcellulose or saline) can be applied between passes to smooth irregular surfaces, preventing differential ablation of elevated lesions. Ablation depth is customized based on the extent of pathology and available stromal reserve; a minimum residual stromal bed of 250 microns is maintained to prevent ectasia risk. A bandage contact lens is placed post-operatively and worn until epithelial healing (typically 3–5 days). Topical antibiotic eye drops (e.g., moxifloxacin) are prescribed to prevent infection, and topical corticosteroids (e.g., fluorometholone) are used to modulate wound healing and reduce haze formation. Recurrence of corneal dystrophy deposits is possible and may require repeat PTK over time.

The prognosis following phototherapeutic keratectomy (PTK) is generally favorable for appropriately selected patients, with the majority achieving meaningful improvement in corneal clarity, surface regularity, and visual acuity. For recurrent corneal erosion syndrome, PTK achieves long-term resolution in over 80% of patients with significantly lower recurrence rates than conservative measures alone, substantially improving quality of life. Visual recovery follows a predictable timeline: epithelial healing occurs within 3–5 days, followed by gradual visual improvement over 4–8 weeks as the corneal surface stabilizes, with full visual benefit taking 3–6 months to manifest. Corneal haze — the most common complication — is usually mild and transient when topical corticosteroids and UV protection are used post-operatively. For corneal dystrophies caused by TGFBI gene mutations (granular, Reis-Bücklers, lattice dystrophies), PTK does not alter the underlying genetic defect — dystrophy deposits recur over years to decades in the majority of patients. However, the procedure can be safely repeated when deposits again impair vision, although each successive treatment reduces available stromal thickness. Patients with corneal scars from infection or trauma may achieve lasting visual improvement if the scar is confined to the anterior stroma. Subepithelial haze formation and induced hyperopic shift are manageable with spectacle correction or concurrent refractive correction. Long-term ophthalmological surveillance is recommended to monitor for recurrence, progressive refractive changes, and adequate residual stromal thickness before any repeat ablation.

Post-PTK care focuses on promoting epithelial healing and preventing complications. Topical antibiotic drops are continued for 5–7 days until the epithelium is healed. Corticosteroid eye drops are tapered over several weeks to prevent subepithelial haze formation. Intensive preservative-free lubricating drops are used to support the ocular surface during healing. UV-blocking sunglasses are worn to prevent ultraviolet-induced corneal haze — UV exposure is avoided for the first 3–6 months post-procedure. Recurrent erosion patients are maintained on lubricating gel at night long-term to prevent recurrence. For corneal dystrophies with genetic mutations (TGFBI), recurrence of deposits is expected over years to decades, and the procedure may be repeated. Potential complications include subepithelial haze, induced hyperopic shift (which may be managed with spectacles, contact lenses, or concurrent refractive correction), delayed epithelial healing, and — rarely — infectious keratitis.

Patients experiencing repeated episodes of sudden-onset severe eye pain, tearing, and blurred vision upon waking should seek evaluation by an ophthalmologist for recurrent corneal erosion syndrome — a condition highly responsive to PTK. Progressive vision deterioration, increasing glare, or halos from known corneal dystrophy that no longer responds to spectacle correction or contact lenses warrants referral to a corneal specialist for assessment of PTK candidacy. Any patient with a corneal scar affecting vision should be evaluated, as PTK may improve clarity if the scar is superficial enough. Sudden worsening of corneal symptoms in a known dystrophy patient — or white corneal deposits visible on self-inspection — should prompt urgent ophthalmological review. An eye specialist should assess whether PTK, corneal transplantation (DALK or PK), or another intervention is most appropriate for each individual case.